Our products use targeted radiation to better inform treatment decisions and deliver personalised therapy in areas of significant unmet medical need.
Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.
Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.
Latest News
See all
Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother, Sandra was diagnosed with glioblastoma (GBM) in 2016 and passed away the same year — less than nine months after diagnosis. We spoke to Courtney about her family’s journey, the…
Read more
